147 related articles for article (PubMed ID: 30813708)
41. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.
Darvishian F; Hummer AJ; Thaler HT; Bhargava R; Linkov I; Asher M; Soslow RA
Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675
[TBL] [Abstract][Full Text] [Related]
42. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study.
Wilder JL; Shajahan S; Khattar NH; Wilder DM; Yin J; Rushing RS; Beaven R; Kaetzel C; Ueland FR; van Nagell JR; Kryscio RJ; Lele SM
Gynecol Oncol; 2004 Feb; 92(2):553-8. PubMed ID: 14766247
[TBL] [Abstract][Full Text] [Related]
43. Expression of Hypoxia-Inducible Factor 1α in Invasive Breast Cancer with Metastasis to Lymph Nodes: Correlation with Steroid Receptors, HER2 and EPO-R.
Badowska-Kozakiewicz A; Sobol M; Patera J
Adv Clin Exp Med; 2016; 25(4):741-50. PubMed ID: 27629849
[TBL] [Abstract][Full Text] [Related]
44. Lymphovascular space invasion (LVSI) is an isolated poor prognostic factor for recurrence and survival among women with intermediate- to high-risk early-stage endometrioid endometrial cancer.
Weinberg LE; Kunos CA; Zanotti KM
Int J Gynecol Cancer; 2013 Oct; 23(8):1438-45. PubMed ID: 24257558
[TBL] [Abstract][Full Text] [Related]
45. Risk Factors for Lymph Node Metastasis among Lymphovascular Space Invasion-Positive Women with Endometrioid Endometrial Cancer Clinically Confined to the Uterus.
Sarı ME; Meydanlı MM; Yalçın I; Şahin H; Çoban G; Çelik H; Kuşçu E; Gungor T; Ayhan A
Oncol Res Treat; 2018; 41(12):750-754. PubMed ID: 30419557
[TBL] [Abstract][Full Text] [Related]
46. [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
Wang Y; Yu M; Yang JX; Cao DY; Zhang Y; Shen K; You Y
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):816-822. PubMed ID: 30585019
[No Abstract] [Full Text] [Related]
47. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
48. L1 Cell Adhesion Molecule (L1CAM) expression in endometrioid endometrial carcinomas: A possible pre-operative surrogate of lymph vascular space invasion.
de Freitas D; Aguiar FN; Anton C; Bacchi CE; Carvalho JP; Carvalho FM
PLoS One; 2018; 13(12):e0209294. PubMed ID: 30557309
[TBL] [Abstract][Full Text] [Related]
49. An exploratory analysis of γ-synuclein expression in endometrioid endometrial cancer.
Zou J; Fan YJ; Meng YQ; Xu H; Fan J
BMJ Open; 2012; 2(2):e000611. PubMed ID: 22535789
[TBL] [Abstract][Full Text] [Related]
50. Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival.
Mauland KK; Wik E; Hoivik EA; Kusonmano K; Halle MK; Berg A; Haugland HK; Øyan AM; Kalland KH; Stefansson IM; Akslen LA; Krakstad C; Trovik J; Werner HM; Salvesen HB
Oncotarget; 2017 Feb; 8(6):9696-9707. PubMed ID: 28039471
[TBL] [Abstract][Full Text] [Related]
51. The Impact of Androgen Receptor Expression on Endometrial Carcinoma Recurrence and Survival.
Mahdi Z; Abdulfatah E; Pardeshi V; Hassan O; Schultz D; Morris R; Cote ML; Elshaikh MA; Bandyopadhyay S; Ali-Fehmi R
Int J Gynecol Pathol; 2017 Sep; 36(5):405-411. PubMed ID: 28277313
[TBL] [Abstract][Full Text] [Related]
52. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
[TBL] [Abstract][Full Text] [Related]
53. Correlation of the SUVmax of FDG-PET and ADC values of diffusion-weighted MR imaging with pathologic prognostic factors in breast carcinoma.
Kitajima K; Yamano T; Fukushima K; Miyoshi Y; Hirota S; Kawanaka Y; Miya M; Doi H; Yamakado K; Hirota S
Eur J Radiol; 2016 May; 85(5):943-9. PubMed ID: 27130054
[TBL] [Abstract][Full Text] [Related]
54. Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression.
Sivridis E; Giatromanolaki A; Koukourakis M; Anastasiadis P
Virchows Arch; 2001 May; 438(5):470-7. PubMed ID: 11407475
[TBL] [Abstract][Full Text] [Related]
55. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
56. Assessing the impact of polysomy-17 on HER2 status and the correlations of HER2 status with prognostic variables (ER, PR, p53, Ki-67) in epithelial ovarian cancer: a tissue microarray study using immunohistochemistry and fluorescent in situ hybridization.
Lin CK; Lin WL; Chen FL; Lee MY; Kuo JF; Ruan A; Tyan YS; Chiang H; Chou MC; Han CP
Int J Gynecol Pathol; 2011 Jul; 30(4):372-9. PubMed ID: 21623202
[TBL] [Abstract][Full Text] [Related]
57. Immunohistochemical Evaluation of Ki-67 and Comparison with Clinicopathologic Factors in Breast Carcinomas.
Aman NA; Doukoure B; Koffi KD; Koui BS; Traore ZC; Kouyate M; Toure I; Effi AB
Asian Pac J Cancer Prev; 2019 Jan; 20(1):73-79. PubMed ID: 30678383
[TBL] [Abstract][Full Text] [Related]
58. [Correlation between estrogen receptor status and clinicopathologic parameters in endometrial cancer: a comparative study by immunohistochemistry using different scoring systems].
Wang Y; Ma XL; Xi CG; Lin J; Ren CX; Liu CR
Zhonghua Bing Li Xue Za Zhi; 2013 Aug; 42(8):509-14. PubMed ID: 24246914
[TBL] [Abstract][Full Text] [Related]
59. Comparison of estrogen and progesterone receptor, Ki-67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiation.
Lax SF; Pizer ES; Ronnett BM; Kurman RJ
Hum Pathol; 1998 Sep; 29(9):924-31. PubMed ID: 9744308
[TBL] [Abstract][Full Text] [Related]
60. [The value of progesterone and estrogen receptors expression in tissue microarray method in prognosis of patients with endometrioid endometrial cancer].
Gottwald L; Kubiak R; Pasz-Walczak G; Sek P; Piekarski J; Szwalski J; Spych M; Chałubińska-Fendler J; Suzin J; Tyliński W; Jeziorski A
Ginekol Pol; 2013 Feb; 84(2):95-101. PubMed ID: 23668054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]